EP4065120A1 - Modulateurs de cftr de type n2-arylmethyl-4-haloalkyl-pyridazin-3-one pour le traitement de la mucoviscidose - Google Patents
Modulateurs de cftr de type n2-arylmethyl-4-haloalkyl-pyridazin-3-one pour le traitement de la mucoviscidoseInfo
- Publication number
- EP4065120A1 EP4065120A1 EP20828531.2A EP20828531A EP4065120A1 EP 4065120 A1 EP4065120 A1 EP 4065120A1 EP 20828531 A EP20828531 A EP 20828531A EP 4065120 A1 EP4065120 A1 EP 4065120A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- trifluoromethyl
- pyridazin
- compound
- mmol
- dimethoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to novel N2-arylmethyl-4-haloalkyl-pyridazin-3-one compounds of Formula I and their use in the treatment and / or prevention of diseases or conditions associated with dysfunction of the cell.
- CFTR channel activity particularly cystic fibrosis.
- Cystic fibrosis is the most frequent lethal hereditary genetic disease in the Caucasian population. In France, every three days, a child is born with this pathology. This disease is caused by an autosomal recessive mutation in the CFTR gene (Cystic Fibrosis Transmembrane conductance Regula ⁇ o ⁇ encoding the protein of the same name, a transmembrane channel5 which allows the exchange of ions, in particular chloride, bicarbonate and small molecules. a multitude of organs including the lungs, pancreas, liver and intestines Respiratory and digestive damage are the main causes of morbidity and mortality in patients.
- CRCM Center for Resources and Skills for Cystic Fibrosis
- the second alternative (by pharmacological therapy) consists in correcting the functioning of the CFTR protein.
- the mutations responsible for the dysfunctions of the chloride channel activity of CFTR are divided into seven classes: absence of synthesis of gene expression (IA), protein (IB), lack of protein targeting to the membrane (II), absence of function membrane (III), reduction of membrane function (IV), reduction of the amount of membrane protein (V) and reduction of membrane stability (VI).
- the most widespread mutation in the population (F508del CFTR - class II) causes this CFTR protein to fold defect on itself, preventing it from integrating into the cell membrane. But other versions of the mutated protein malfunction although they are present in the membrane (G551 D mutation for example - class III).
- Vertex has also developed the combination of two molecules (one corrective and the other potentiator) Orkambi ® (combination of Lumacaftor, a corrector of CFTR, and Ivacaftor) to treat subjects carrying the most frequent mutation F508del (detected in around 80% of patients on at least one allele, 2,500 patients in France).
- Orkambi ® combination of Lumacaftor, a corrector of CFTR, and Ivacaftor
- Patent application US 2014/274933 A1 describes compounds of the phthalazinone type and their use in the treatment of pathologies involving the CFTR protein and in particular cystic fibrosis.
- Patent application WO 2016/066973 A1 describes fluorinated pyridazin-3-ones and their use as a PDE4 inhibitor for the treatment of the inflammatory component of bronchopulmonary diseases. However, these compounds do not target the CFTR channel.
- the inventors have now succeeded in developing new compounds making it possible to restore the activity of the CFTR channel.
- the invention therefore relates to compounds of Formula I, their pharmaceutically acceptable salts and solvates as well as the use of these compounds, or their solvates or compositions for the treatment and / or prevention of diseases or conditions associated with dysfunction. of the activity of the CFTR channel.
- the invention relates to compounds of Formula I: [0015] [Chem. 1] or its pharmaceutically acceptable salts or solvates, wherein
- R 1 is cycloalkyl, heteroaryl or aryl optionally substituted with a group selected from alkyl, alkoxy and arylalkyl;
- R 2 is F1 or alkyl
- R 3 is cycloalkyl, heteroaryl or aryl optionally substituted with one or two groups independently selected from alkyl, alkoxy and haloalkoxy;
- R 4 is F1 or alkyl
- RF is haloalkyl
- ! is a single bond or a double bond.
- the invention relates to pharmaceutical compositions comprising at least one compound according to the invention or one of its pharmaceutically acceptable salts or solvates and at least one pharmaceutically acceptable excipient
- the invention also relates to the use of the compounds according to the invention or one of its salts or pharmaceutically solvates. acceptable for restoration of CFTR channel activity. Accordingly, the compounds of the invention and their pharmaceutically acceptable solvates are useful in the treatment and / or prevention of diseases or conditions associated with dysfunction of CFTR channel activity.
- the invention therefore also relates to the compounds according to the invention for use as a medicament, in particular in the treatment and / or prevention of diseases or conditions associated with a dysfunction of the activity of the CFTR channel, in particular cystic fibrosis.
- compositions comprising at least one compound according to the invention or one of its pharmaceutically acceptable salts or solvates and at least one additional therapeutic agent.
- the invention relates to compounds of Formula I as well as their pharmaceutically acceptable solvates.
- R 1 is C5 to C7 cycloalkyl, C5 to C6 heteroaryl, or C6 to C10 aryl, optionally substituted with a group selected from C1 to C6 alkyl, C1 to C4 alkoxy and C1 to C4 arylalkyl; preferably R 1 is C5 to C6 cycloalkyl, C5 to C6 heteroaryl, or C6 aryl, optionally substituted with a group selected from C1 to C6 alkyl, C1 to C2 alkoxy and C1 to C2 arylalkyl; more preferably R 1 is cyclohexyl, thiophenyl, pyridinyl or phenyl, optionally substituted with a group chosen from C1 to C4 alkyl, C1 to C2 alkoxy and C1 to C2 arylalkyl; more preferably R 1 is cyclohexyl, thiophenyl, or phenyl, optionally substituted with a
- R 3 is C5 to C7 cycloalkyl, C4 to C6 heteroaryl, or C6 to C10 aryl, optionally substituted with one or two groups independently selected from C1 to C6 alkyl, C1 to C4 alkoxy and C1 to C4 haloalkoxy; preferably R 3 is C5 to C6 cycloalkyl, C4 to C6 heteroaryl or C6 aryl, optionally substituted with one or two groups independently selected from C1 to C6 alkyl, C1 to C2 alkoxy and C1 to C2 haloalkoxy ; more preferably, R 3 is cyclohexyl, thiophenyl, pyridinyl or phenyl optionally substituted with one or two groups independently selected from C1 to C4 alkyl, C1 to C2 alkoxy and C1 to C2 haloalkoxy; more preferably R 3 is cyclohexyl, pyridinyl or phenyl, optionally
- R 4 is H or C1-C6 alkyl; preferably R 4 is H or C1 to C4 alkyl; more preferably R 4 is H or C1 to C2 alkyl; more preferably, R 4 is H or methyl; even more preferably, R 4 is H;
- RF is C1-C6 haloalkyl; preferably, RF is C1-C4 haloalkyl; more preferably RF is C1 to C2 haloalkyl; more preferably, RF is C1 to C2 fluoroalkyl; even more preferably, RF is trifluoromethyl.
- the inventors believe that the ability of the compounds of the invention to restore the activity of the CFTR channel is obtained in particular thanks to the group R 1 located in the benzylic position relative to the pyridazinone or dihydropyridazinone nucleus.
- the compounds of the invention are those of Formula II:
- R 1 and R 2 are as defined above with respect to Formula I, and R 5 and R 6 are independently of each other selected from alkoxy and haloalkoxy; preferably R 5 and R 6 are independently selected from C1 to C4 alkoxy and C1 to C4 haloalkoxy; more preferably R 5 and R 6 are independently selected from C1 to C2 alkoxy and C1 to C2 haloalkoxy; more preferably, R 5 and R 6 are independently chosen from methoxy and difluoromethoxy.
- R 5 and R 6 are independently of each other selected from alkoxy and haloalkoxy; preferably R 5 and R 6 are independently selected from C1 to C4 alkoxy and C1 to C4 haloalkoxy; more preferably, R 5 and R 6 are independently selected from C1 to C2 alkoxy and C1 to C2 haloalkoxy; more preferably, R 5 and R 6 are independently chosen from methoxy and difluoromethoxy.
- Other preferred compounds of formula II are those of
- the compounds of the invention are those of Formula III:
- R 5 and R 6 are independently of each other selected from alkoxy and haloalkoxy; preferably R 5 and R 6 are independently selected from C1 to C4 alkoxy and C1 to C4 haloalkoxy; more preferably R 5 and R 6 are independently selected from C1 to C2 alkoxy and C1 to C2 haloalkoxy; more preferably, R 5 and R 6 are independently chosen from methoxy and difluoromethoxy.
- Other preferred compounds of formula III are those of formula IIIc:
- the invention relates to the use of the compounds of the invention or their pharmaceutically acceptable salts or solvates for the restoration of the activity of the CFTR channel.
- the compounds of the invention are thus useful in the treatment and / or prevention of diseases or conditions with a dysfunction of the activity of the CFTR channel.
- the invention therefore also relates to the compounds according to the invention or their pharmaceutically acceptable salts or solvates for use as medicaments, in particular for use in the treatment and / or prevention of diseases or conditions associated with a dysfunction of the activity of the drug. CFTR channel.
- the invention relates to compounds of formula I as described above for use in the treatment of cystic fibrosis.
- the present invention also relates to a method of treating the diseases and conditions indicated above comprising the administration, to a patient, of an effective dose of a compound according to the invention. , or one of its pharmaceutically acceptable salts or solvates.
- the patient is a warm blooded animal, more preferably a human.
- the invention relates to a method of restoring the activity of the CFTR channel in a patient, preferably a warm-blooded animal, more preferably a human, in need thereof, said method comprising the administration to this patient of an effective dose of a compound according to the invention, or of a pharmaceutically acceptable salt or solvate thereof.
- the compounds of the invention, their pharmaceutically acceptable salts or solvates can be administered in the context of a combination therapy.
- embodiments comprising the co-administration of compositions or drugs which contain, in addition to a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof. here as an active ingredient, one or more additional therapeutic agents and / or active ingredients.
- Such multiple treatment regimens often referred to as combination therapy, can be used in the treatment and / or prevention of cystic fibrosis.
- the methods of treatment and the pharmaceutical compositions of the present invention can use the compounds of the invention or their acceptable pharmaceutical salts or solvates in the form of monotherapy, but these methods and compositions can also be used in the form of combination therapy.
- one or more compounds of the invention or their pharmaceutically acceptable salts or solvates are co-administered in combination with one or more other therapeutic agents.
- additional therapeutic agents include, but are not limited to, Ivacaftor, Lumacaftor and / or Tezacaftor, preferably Ivacaftor.
- additional therapeutic agents are selected from Ivacaftor and Lumacaftor.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound of Formula I or one of its pharmaceutically acceptable salts or solvates and at least one pharmaceutically acceptable excipient.
- Said excipients are chosen, according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
- the invention also relates to pharmaceutical compositions which contain, in addition to a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof as an active ingredient, one or more additional therapeutic agents and / or active ingredients.
- the pharmaceutical composition of the present invention can be chosen from pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration.
- the active ingredient of Formula I above, or its pharmaceutically acceptable solvate can be administered in unit form of administration, in admixture with conventional pharmaceutical excipients, to animals and humans for treatment and / or the prevention of the diseases or conditions indicated above.
- Suitable unit administration forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular, intranasal administration forms , by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants.
- the compounds according to the invention can be used in creams, gels, ointments or lotions.
- it is a pharmaceutical composition for oral administration.
- Such appropriate forms of administration which may be in solid, semi-solid or liquid form depending on the mode of administration, are generally known to those skilled in the art, reference being made to the latest edition of the book “Remington's Pharmaceutical Sciences ”.
- halo or halo, alone or as part of another group, denotes fluoro, chloro, bromo, or iodo. Preferred halo groups are chloro and fluoro, fluoro being particularly preferred.
- alkyl (e) alone or as part of another group, denotes a hydrocarbon radical of formula CnhLn + i in which n is an integer greater than or equal to 1.
- haloalkyl (e) or “haloalkyl (e)", alone or as part of another group, denotes an alkyl radical as defined above in which one or more hydrogen atoms are replaced by a halo group as defined above.
- the haloalkyl radicals according to the present invention can be linear or branched, and comprise, without being limited thereto , radicals of formula C n F2n + i in which n is an integer greater than or equal to 1, preferably an integer between 1 and 10.
- Preferred haloalkyl radicals include trifluoromethyl, difluoromethyl, fluoromethyl, pentafluoroethyl, heptafluoro-n-propyl, nonafluoro-n-butyl, 1,1,1 -trifluoro-n-butyl, 1, 1, 1 -trifluoro-n-pentyl and 1, 1, 1 -trifluoro-n-hexyl, trifluoromethyl and difluoromethyl being particularly preferred.
- alkoxy denotes an alkyl radical as defined above bonded to an oxygen atom.
- Preferred alkoxy radicals include methoxy, ethoxy, propyloxy, and butyloxy, with methoxy being particularly preferred.
- haloalkoxy or "haloalkoxy", alone or as part of another group, denotes a haloalkyl radical as defined above bonded to an oxygen atom.
- Preferred haloalkoxy radicals include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoroethoxy, difluoroethoxy, trifluoroethoxy, chloroethoxy, particularly preferred dichlorichoethoxyoethoxy and trichloroethoxy, difluoroethoxy, trifluoroethoxy, chloroethoxy, dichlorichoethoxyoethoxy and trichloroethoxy, and dichloroethoxyoethoxy, and
- cycloalkyl (e) denotes a saturated mono-, di- or tri-cyclic hydrocarbon radical having 3 to 12 carbon atoms, in particular 5 to 10. carbon atoms, more particularly 6 to 10 carbon atoms.
- Suitable cycloalkyl radicals include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, adamantyl, especially adamant-1-yl and adamant-2-yl, 1-decalinyl.
- Preferred cycloalkyl groups include cyclopropyl, cyclohexyl, and cycloheptyl.
- a particularly preferred cycloalkyl group is cyclohexyl.
- aryl (e) denotes a polyunsaturated aromatic hydrocarbon radical having a single ring (phenyl) or several aromatic rings condensed together (for example naphthyl) typically containing 5 to 12 atoms, preferably 6 to 10, in which at least one of the rings is aromatic.
- a particularly preferred aryl group is phenyl.
- heteroaryl (e) designates, without being limited thereto, aromatic rings or ring systems containing one to two rings condensed between them, typically containing 5 to 12 atoms, in which at least one of the rings is aromatic, and in which one or more carbon atoms in one or more of these rings are replaced by oxygen, nitrogen and / or sulfur atoms, the heteroatoms of nitrogen and sulfur can optionally be oxidized and the nitrogen heteroatoms can optionally be quaternized.
- Preferred but non-limiting heteroaryl groups are pyridinyl, pyrrolyl, furanyl, thiophenyl. Particularly preferred heteroaryl groups are thiophenyl and pyridinyl.
- the compounds of the invention containing a basic functional group can be in the form of pharmaceutically acceptable salts.
- the pharmaceutically acceptable salts of the compounds of the invention containing one or more basic functional groups include in particular their acid addition salts. Suitable acid addition salts are formed from acids which form non-toxic salts.
- salts include acetate, adipate, aspartate, benzoate, besylate, bicarbonate / carbonate, bisulfate / sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydrochloride / iodide, isethionate, lactate, malate , the maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, saccharate, stearate, succinate, tanna
- the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
- the degree of ionization in salt can vary from fully ionized to almost non-ionized.
- the compounds of Formula I can exist in the form of solvates, namely in the form of associations or combinations with one or more molecules of solvent, such as, for example, ethanol or water.
- solvent such as, for example, ethanol or water.
- the compounds of the invention are the compounds of Formula I and their solvates as defined above, including all their polymorphs and crystalline forms, their prodrugs and compounds or solvates bearing an isotopic label.
- patient denotes a warm-blooded animal, preferably a human, who is awaiting or receiving medical treatment.
- human designates subjects of both sexes and at any stage of development (that is to say neonatal, infantile, juvenile, adolescent and adult). In one embodiment, it is a teenager or an adult, preferably an adult.
- treat and “treatment” are to be understood in their general meaning and thus include the amelioration and abrogation of a pathological condition.
- prevent and “prevention” denote the fact of avoiding or delaying the onset of a disease or condition and related symptoms, thus excluding a patient from developing a disease or condition or reducing the risk of 'a patient to develop a disease or condition.
- terapéuticaally effective dose or “effective dose” denotes the dose of active principle (compound of Formula I) which is sufficient to achieve the desired therapeutic or prophylactic result in the patient to whom it is administered.
- pharmaceutically acceptable denotes that a compound or component is not harmful to the patient and that in the context of a pharmaceutical composition it is compatible with the other components.
- FIG. 1 shows the in vitro screening of the restoration of the activity of the CFTR channel of compounds 1 and 4 according to the invention in comparison with that of Ivacaftor, Lumacaftor and Orkambi.
- FIG. 2 shows the in vitro screening of the restoration of the activity of the CFTR channel of compounds 1 to 6 according to the invention.
- Fig. 3 shows the in vitro screening of the restoration of the activity of the CFTR channel of compounds 1 to 6 according to the invention.
- FIG. 3 shows the in vitro screening of the restoration of the activity of the CFTR channel of compounds 7 to 11 and 13 according to the invention.
- FIG. 4 shows the in vitro evaluation of the restoration of channel activity
- FIG. 5 shows the in vitro evaluation of the restoration of the activity of the CFTR channel of compounds 1 and 4 according to the invention in combination with Ivacaftor and Lumacaftor in comparison with Orkambi.
- the preparative column chromatographies were carried out by the chromatographic technique on silica gel.
- the so-called normal silica column chromatographies are carried out with a 60 ACC Chromagel SDS® silica gel with a particle size of 70 to 200 ⁇ m.
- the chromatographies on a “flash” silica column are carried out with a silica gel with a particle size of 40 to 63 ⁇ m from the Kieselgel 60 Merck® brand.
- the NMR analyzes were carried out on a BRUKER 199 DPX 300 spectrometer with a 7.05 T superconducting magnet (1 H resonates at 300 MHz and 13C at 75 MHz. The spectra are recorded in solution either in deuterated chloroform (CDCl3).
- TMS tetramethylsilane
- CD3OD deuterated methanol
- DMSO-d6 deuterated dimethylsulfoxide
- the low (MS) and high resolution (H REIMS) mass spectra in electronic impact (IE) at -70eV are recorded on a WATERS MICROMASS GCT CA 170 device.
- the mass spectra by electrospray ionization (ESI), in positive mode (ESI +) or negative mode (ESI-) are recorded on a THERMOFINNIGAN brand MSQ device coupled to a quadrupole detector.
- Solvents, reagents and starting materials have been purchased from well known chemical suppliers such as Sigma Aldrich, Acros Organics, Fluorochem, Eurisotop, VWR International, Sopachem and Polymer and, unless otherwise specified, have been used without additional purification.
- TA ambient temperature
- TBAB tetrabutylammonium bromide
- TFA trifluoroacetic acid
- Reagents and conditions (i) THF, 0-25 ° C, 10h; (ii) TFA, water, reflux; (iii) AcOH, reflux or EtOH, TA; (iv) CuCl 2 , CHsCN, reflux, 4h; (v) K2CO3, TBAB, CHsCN, reflux, 4h.
- the compound [a] is reacted with a potassium enolate, in tetrahydrofuran (THF) as solvent, at a temperature between 0 and 25 ° C for a period of the order of 10 h.
- THF tetrahydrofuran
- This intermediate of formula [b] is then subjected to an acid hydrolysis reaction in the presence of trifluoroacetic acid (TFA) and water under reflux heating.
- TFA trifluoroacetic acid
- This acid hydrolysis reaction allows a second thioester type intermediate of formula [c] to be obtained.
- the intermediate compound [c] can then be subjected to a condensation reaction with hydrazine (NH2NH2).
- the reaction is carried out in the presence of glacial acetic acid, in a reflux heater, for a period of about 4 to 5 hours. After cooling, the solvent is advantageously evaporated off in vacuo.
- the compound [d] according to the invention is then purified by chromatography column. According to a preferred embodiment, the purification of said compound [d] is carried out by chromatography on silica gel, advantageously in the presence of a mixture of petroleum ether and ethyl acetate.
- the compound [d] is mixed, under an argon atmosphere in acetonitrile, with cupric chloride. This mixture is brought to reflux for 4 h. After cooling, the reaction crude is purified by a chromatographic column to make it possible to obtain the compounds [e].
- the compound [e] is mixed, under an argon atmosphere in acetonitrile, with potassium carbonate (K2CO3) and tetrabutylammonium bromide (TBAB). After 2 hours, the benzyl halides are added to the reaction medium. This mixture is brought to reflux for 4 h. After cooling, the reaction crude is purified by chromatography column to make it possible to obtain the compounds according to the invention.
- K2CO3 potassium carbonate
- TBAB tetrabutylammonium bromide
- certain compounds according to the invention can be obtained after direct addition of benzylhydrazine functionalized on intermediate [c].
- the intermediate products [f] obtained then being oxidized in the presence of cupric chloride in acetonitrile.
- the mixture is brought to reflux for 4 h.
- the reaction crude is purified by a chromatographic column to make it possible to obtain the compounds according to the invention.
- Compound [b1] is prepared according to the general procedure for the synthesis of synthetic intermediates [b] from (perfluoroprop-1-en-1,1-diyl) bis (ethylsulfane) [a] (500 mg, 2, 13 mmol, 1 eq), 1- (3,4-dimethoxyphenyl) ethanone (471 mg, 2.56 mmol, 1, 2 eq) and potassium hydride (683 mg, 4.26 mmol, 2 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 90/10) in the form of a yellow liquid. Yield: 70% (587 mg).
- Compound [b2] is prepared according to the general procedure for the synthesis of synthetic intermediates [b] from (perfluoroprop-1-en-1,1-diyl) bis (ethylsulfane) [a] (187 mg, 0, 8 mmol, 1 eq), 1- (4- (difluoromethoxy) -3- methoxyphenyl) ethanone (208 mg, 0.96 mmol, 1, 2 eq) and potassium hydride (257 mg, 1, 6 mmol, 2 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 98/2) in the form of colorless crystals. Yield: 85% (291 mg).
- Compound [b3] is prepared according to the general procedure for the synthesis of synthetic intermediates [b] from (perfluoroprop-1-en-1,1-diyl) bis (ethylsulfane) [a] (700 mg, 3, 0 mmol, 1 eq), 1-cyclohexylethanone (519 m ⁇ , 3.6 mmol, 1, 2 eq) and potassium hydride (962 mg, 6.0 mmol, 2 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 99.5 / 0.5) in the form of a pale yellow liquid. Yield: 74% (760 mg).
- Compound [b4] is prepared according to the general procedure for the synthesis of synthetic intermediates [b] from (perfluoroprop-1-en-1,1-diyl) bis (ethylsulfane) [a] (469 mg, 2, 0 mmol, 1 eq), 1- (pyridin-2-yl) ethanone (291 mg, 2.4 mmol, 1, 2 eq) and potassium hydride (642 mg, 4.0 mmol, 2 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 95/5) as a yellow liquid. Yield: 70% (561 mg).
- mixture 3 is neutralized with a saturated aqueous solution, preferably with NaHCO3;
- the aqueous phase is extracted from mixture 3, preferably with methylene chloride;
- the compound [cl] is prepared according to the general procedure for the synthesis of synthetic intermediates [c] from 1- (3,4-dimethoxyphenyl) -4,4- bis (ethylthio) -3- (trifluoromethyl) but -3-en-1-one [b1] (594 mg, 1.5 mmol, 1 eq), TFA (1.04 mL, 13.6 mmol, 9 eq) and water (0.082 mL, 4, 53 mmol, 3 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 90/10) in the form of a yellow oil. Yield: 89% (470 mg).
- the compound [c2] is prepared according to the general procedure for the synthesis of synthetic intermediates [c] from 1 - (4-difluoromethoxy) -3-methoxyphenyl) -4,4-bis (ethylthio) -3- ( trifluoromethyl) but-3-en-1 -one [b2] (290 mg, 0.67 mmol, 1 eq), TFA (0.467 mL, 6.06 mmol, 9 eq) and water (0.036 mL, 2 , 01 mmol, 3 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 95/5) in the form of an orange liquid. Yield: 78% (200 mg).
- Compound [c3] is prepared according to the general procedure for the synthesis of synthetic intermediates [c] from 1 -cyclohexyl-4,4-bis (ethylthio) -3- (trifluoromethyl) but-3-en-1 -one [b3] (750 mg, 2.20 mmol, 1 eq), TFA (1.527 mL, 19.8 mmol, 9 eq) and water (0.119 mL, 6.60 mmol, 3 eq) in the form of a brown liquid. Yield: 95% (618 mg).
- the compound [c4] is prepared according to the general procedure for the synthesis of synthetic intermediates [c] from 4,4-bis (ethylthio) -1 - (pyridin-2-yl) -3- (trifluoromethyl) but -3-en-1 -one [b4] (550 mg, 1.64 mmol, 1 eq), TFA (1.17 mL, 14.80 mmol, 9 eq) and water (0.088 mL, 4, 92 mmol, 3 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 90/10) under the shape of a yellow lacquer. Yield: 26% (120 mg).
- Compound [d1] is prepared according to the general procedure for the synthesis of synthetic intermediates [d] from S-ethyl 4- (3 ', 4'-dimethoxyphenyl) -2-trifluoromethyl-4-oxo-butanethioate [ cl] (500 mg, 1.4 mmol, 1 eq) and hydrazine (35% in water) (1.616 mL, 17.8 mmol, 12.5 eq) and obtained after purification by chromatography on a column of flash silica (CH2Cl2 / MeOH: 99/1) in the form of a white solid. Yield: 76% (320 mg).
- the compound [d2] is prepared according to the general procedure for the synthesis of synthesis intermediates [d] from 4- (4- (difluoromethoxy) -3- S-ethyl [c2] methoxyphenyl) -4-oxo-2- (trifluoromethyl) butanethioate (100 mg, 0.25 mmol, 1 eq) and hydrazine (35% in water) (0.282 mL, 3 , 13 mmol, 12.5 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 80/20) in the form of a beige solid. Yield: 100% (086 mg).
- the mixture 5 is brought to reflux, preferably for a period of around 4 hours;
- Compound [e1] is prepared according to the general procedure for the synthesis of synthetic intermediates [e] from 6- (3 ', 4'-dimethoxyphenyl) -4-trifluoromethyl-4,5-dihydropyridazin-3 (2 / - /) - one [d1] (300 mg, 1.0 mmol, 1 eq) and copper (II) chloride (269 mg, 2.0 mmol, 2 eq) and obtained after purification by chromatography on a column of flash silica (CH2Cl2 / MeOH: 98/2) as an intense yellow solid. Yield: 85% (256 mg).
- the compound [e2] is prepared according to the general procedure for the synthesis of synthesis intermediates [e] from 6- (4- (difluoromethoxy) phenyl) -4- (trifluoromethyl) -4,5-dihydropyridazin-3 ( 2 / - /) - one [d2] (16 mg, 0.05 mmol, 1 eq) and copper (II) chloride (13 mg, 0.10 mmol, 2 eq) and obtained after purification by chromatography on a flash silica column (EP / AE: 80/20) in the form of beige crystals. Yield: 81% (13 mg).
- the compound [fl] is prepared according to the general procedure for the synthesis of synthetic intermediates [f] from S-ethyl 4- (3 ', 4'-dimethoxyphenyl) -2-trifluoromethyl-4-oxo-butanethioate [ cl] (100 mg, 0.29 mmol, 1 eq) and dihydrochlorinated benzylhydrazine (718 mg, 3.68 mmol, 12.5 eq) and obtained by purification by chromatography on a flash silica column (EP / AE: 80 / 20) as a beige solid. Yield: 47% (54 mg).
- the compound [f2] is prepared according to the general procedure for the synthesis of synthetic intermediates [f] from S-ethyl 4- (3 ', 4'-dimethoxyphenyl) -2-trifluoromethyl-4-oxo-butanethioate [ cl] (100 mg, 0.29 mmol, 1 eq) and dihydrochlorinated 4-methylbenzylhydrazine (626 mg, 3.63 mmol, 12.5 eq) and isolated after purification by chromatography on a flash silica column (EP / AE: 80/20) in the form of a white solid. Yield: 32% (40 mg).
- Compound [f3] is prepared according to the general procedure for the synthesis of synthetic intermediates [f] from S-ethyl 4- (3 ', 4'-dimethoxyphenyl) -2-trifluoromethyl-4-oxo-butanethioate [ cl] (100 mg, 0.29 mmol, 1 eq) and 4-methoxylbenzylhydrazine (789 mg, 3.63 mmol, 12.5 eq) and isolated after purification by chromatography on a flash silica column (EP / AE: 80/20) as a yellow solid. Yield: 51% (62 mg).
- the compound [f4] is prepared according to the general procedure for the synthesis of synthetic intermediates [f] from 4- (4- (difluoromethoxy) -3-methoxyphenyl) -4-oxo-2- (trifluoromethyl) butanethioate of S -ethyl [c2] (100 mg, 0.26 mmol, 1 eq) and 4-methoxylbenzylhydrazine (703 mg, 3.24 mmol, 12.5 eq) and isolated after purification by chromatography on a flash silica column (EP / AE: 80/20) as a beige solid. Yield: 62% (0.074 g).
- Compound [f5] is prepared according to the general procedure for the synthesis of synthetic intermediates [f] from S-ethyl 4-cyclohexyl-4-oxo-2- (trifluoromethyl) butanethioate [c3] (150 mg, 0 , 50 mmol, 1 eq) and dihydrochlorinated benzylhydrazine (1257 mg, 6.25 mmol, 12.5 eq) and isolated after purification by chromatography on a flash silica column (EP / AE: 90/10) in the form of a beige oil. Yield: 83% (141 mg).
- Compound [f6] is prepared according to the general procedure for the synthesis of synthetic intermediates [f] from S-ethyl 4- (3 ', 4'-dimethoxyphenyl) -2-trifluoromethyl-4-oxo-butanethioate [ cl] (100 mg, 0.29 mmol, 1 eq) and hydrochlorinated cyclohexylmethylhydrazine (597 mg, 3.63 mmol, 12.5 eq) and isolated after purification by chromatography on a flash silica column (EP / AE: 90 / 10) as a yellow oil. Yield: 25% (29 mg).
- the compound [f7] is prepared according to the general procedure for the synthesis of synthetic intermediates [f] from S-ethyl 4-oxo-4- (pyridin-2-yl) -2- (trifluoromethyl) butanethioate [c4] (73 mg, 0.25 mmol, 1 eq) and dihydrochlorinated benzylhydrazine (74 mg, 0.38 mmol, 12.5 eq) and obtained after purification by chromatography on a flash silica column (EP / EA: 80/20) in the form of an orange lake. Yield: 100% (83 mg).
- Example 1 2-benzyl-6- (3,4-dimethoxyphenyl) -4- (trifluoromethyl) pyridazin-3 (2 7) -one
- Example 2 6- (3,4-dimethoxyphenyl) -2- (4-methylbenzyl) -4- (trifluoromethyl) pyridazin-3 (2H) -one
- Example 3 6- (3,4-dimethoxyphenyl) -2- (4-methoxybenzyl) -4- (trifluoromethyl) pyridazin-3 (2H) -one
- Example 4 6- (4- (difluoromethoxy) -3-methoxyphenyl) -2- (4-methoxy-benzyl) -4- (trifluoromethyl) pyridazin-3 (2H) -one
- Example 6 2- (cyclohexylmethyl) -6- (3,4-dimethoxyphenyl) -4- (trifluoromethyl) pyridazin-3 (2H) -one
- the pyridazinone N2-H [e1] (50 mg, 0.17 mmol, 1 eq) is dissolved in acetonitrile with K 2 CC> 3 (59 mg, 0.43 mmol, 2.5 eq), Bu4NBr (3 mg, 0.009 mmol, 0.05 eq), and 3-methylthiophene chloride (25 mg, 0.18 mmol, 1.1 eq), this constitutes mixture 6 (v).
- This mixture is heated to 60 ° C. for a period of the order of 2 to 4 hours. After cooling, the solvent is evaporated off and the crude is taken up in water and extracted with methylene chloride.
- reaction crude After drying the organic phase, filtration, evaporation under reduced pressure, the reaction crude is purified by chromatography on a flash silica column (EP / AE: 80/20) to obtain compound 7 in the form of yellow crystals. Yield: 70% (47 mg).
- Example 8 6- (4- (difluoromethoxy) -3-methoxyphenyl) -2- (thiophen-3- ylmethyl) -4- (trifluoromethyl) pyridazin-3 (2H) -one
- reaction crude After drying the organic phase, filtration, evaporation under reduced pressure, the reaction crude is purified by chromatography on a flash silica column (EP / AE: 80/20) to obtain compound 8 in the form of beige crystals. Yield: 78% (50 mg).
- Example 9 6- (4- (difluoromethoxy) -3-methoxyphenyl) -2- (1-phenyl-ethyl) -4- (trifluoromethyl) pyridazin-3 (2A7) -one
- Example 10 6- (3,4-dimethoxyphenyl) -2- (4-phenethylbenzyl) -4-
- reaction crude After drying the organic phase, filtration, evaporation under reduced pressure, the reaction crude is purified by chromatography on a flash silica column (EP / AE: 85/15) to obtain compound 10 in the form of a bright yellow lake. Yield: 65% (55 mg).
- Example 11 6- (4- (difluoromethoxy) -3-methoxyphenyl) -2- (4-phenethyl-benzyl) -4- (trifluoromethyl) pyridazin-3 (2A7) -one
- reaction crude After drying the organic phase, filtration, evaporation under reduced pressure, the reaction crude is purified by chromatography on a flash silica column (EP / AE: 90/10) to obtain compound 11 in the form of white crystals. Yield: 86% (69 mg).
- Example 12 2-benzyl-6- (3,4-dimethoxyphenyl) -4- (trifluoromethyl) -4,5- dihydropyridazin-3 (27) -one
- Example 13 6- (3,4-dimethoxyphenyl) -2- (4-methylbenzyl) -4- (trifluoromethyl) -4,5-dihydropyridazin-3 (2H) -one
- Example 15 6- (4- (difluoromethoxy) -3-methoxyphenyl) -2- (4- methoxybenzyl) -4- (trifluoromethyl) -4,5-dihydropyridazin-3 (2A7) -one
- Example 17 6- (4- (difluoromethoxy) -3-methoxyphenyl) -2- (4- methylbenzyl) -4- (trifluoromethyl) -4,5-dihydropyridazin-3 (2A7) -one
- Example 18 6- (3,4- (dimethoxyphenyl) -2- (1-phenylethyl) -4-
- reaction crude After drying the organic phase, filtration, evaporation under reduced pressure, the reaction crude is purified by chromatography on a flash silica column (EP / EA: 90/10) to obtain compound 18 in the form of a yellow lake. Yield: 57% (38 mg).
- Example 19 2-benzyl-6- (pyridin-2-yl) -4- (trifluoromethyl) -4,5-dihydro pyridazin-3 (2H) -one
- Example 20 2- (4-methylbenzyl) -6- (pyridin-2-yl) -4- (trifluoromethyl) - 4,5-dihydropyridazin-3 (2H) -one
- Example 21 2- (4-methoxybenzyl) -6- (pyridin-2-yl) -4- (trifluoromethyl) - 4,5-dihydropyridazin-3 (2H) -one
- Example 22 6- (4- (difluoromethoxy) -3-methoxyphenyl) -2- (4-methyl benzyl) -4- (trifluoromethyl) -4,5-dihydropyridazin-3 (2H) -one
- BIOLOGICAL ASSESSMENT To evaluate the action of the compounds according to the invention on the restoration of the CFTR activity, said compounds were tested in vitro using a suitable Premo Halid Sensor kit (Invitrogen).
- the principle is based on the measurement of fluorescence (at 515-530 nm) emitted by a probe in the presence or absence of compounds of the N-benzylpyridazinones type making it possible to modulate the activity of the CFTR protein and therefore to restore the. chloride activity of the channel.
- the activity of the CFTR channel is stimulated using a solution composed of forskolin, 3- / sobutyl-1-methylxanthine and apigenin (each component to a concentration of 10 mM).
- An iodine solution 140 mM is then added and the fluorescence is recorded using a plate reader (400 ms / point; Ft) over a period of 60s (baseline; F0).
- the decrease in the Ft / FO ratio represents the restoration of the chloride activity of the CFTR channel.
- a specific inhibitor of the CFTR channel (CFTRinh-172 (10 mM)) is used to verify the signal emitted by the untreated osteoblasts. In the presence of this inhibitor (control) no decrease in fluorescence is observed.
- the slopes of the signals obtained are processed in non-linear regressions and correlated with the level of the conductance of the chloride ions.
- the measurements indicate a restoration of the activity of the CFTR channel (150% on average) of compounds 1 and 4 according to the invention compared to reference substances (Ivacaftor, Lumacaftor, Orkambi).
- FIG. 1 shows that compounds 1 and 4 make it possible to obtain a better restoration of the activity of the CFTR channel than those obtained with Ivacaftor and Lumacaftor, and that compound 1 makes it possible to obtain a restoration of the activity of the CFTR channel similar to that obtained with Orkambi.
- Figure 4 shows the analysis at 2 seconds of the activity of the CFTR channel and supports the effect of compounds 1 to 8 and 10 to 18 according to the invention according to the invention compared to the basal condition. These results show a restoration of CFTR channel activity from 102% to 152% on average.
- Figure 5 shows the in vitro evaluation of the restoration of the activity of the CFTR channel of compounds 1 and 4 according to the invention in combination with Ivacaftor or Lumacaftor, in comparison with Orkambi.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1913404A FR3103701B1 (fr) | 2019-11-28 | 2019-11-28 | Composés de typen2-arylméthyl-4-haloalkyl-pyridazin-3-one et leur utilisation |
PCT/FR2020/052228 WO2021105641A1 (fr) | 2019-11-28 | 2020-11-30 | Modulateurs de cftr de type n2-arylmethyl-4-haloalkyl-pyridazin-3-one pour le traitement de la mucoviscidose |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4065120A1 true EP4065120A1 (fr) | 2022-10-05 |
Family
ID=70295227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20828531.2A Pending EP4065120A1 (fr) | 2019-11-28 | 2020-11-30 | Modulateurs de cftr de type n2-arylmethyl-4-haloalkyl-pyridazin-3-one pour le traitement de la mucoviscidose |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230013304A1 (fr) |
EP (1) | EP4065120A1 (fr) |
CN (1) | CN114945368A (fr) |
CA (1) | CA3163176A1 (fr) |
FR (1) | FR3103701B1 (fr) |
WO (1) | WO2021105641A1 (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000247959A (ja) * | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−3−オン誘導体及びこれを含有する医薬 |
CN1759103A (zh) * | 2003-03-18 | 2006-04-12 | 兴和株式会社 | 水溶性苯基哒嗪衍生物及含有该衍生物的医药品 |
WO2008121877A2 (fr) * | 2007-04-02 | 2008-10-09 | Institute For Oneworld Health | Composés inhibiteurs de cftr et leurs utilisations |
BR112015023328A2 (pt) | 2013-03-13 | 2017-07-18 | Flatley Discovery Lab | compostos de piridazinona e métodos para o tratamento de fibrose cística |
FR3027901B1 (fr) | 2014-10-31 | 2018-03-16 | Universite De Reims Champagne Ardenne | Nouveaux procedes appartenant a la famille des pyridazinones. |
EP3532467A1 (fr) * | 2016-10-26 | 2019-09-04 | Proteostasis Therapeutics, Inc. | Composés de pyridazine, compositions et méthodes permettant de moduler cftr |
-
2019
- 2019-11-28 FR FR1913404A patent/FR3103701B1/fr active Active
-
2020
- 2020-11-30 EP EP20828531.2A patent/EP4065120A1/fr active Pending
- 2020-11-30 CN CN202080092401.8A patent/CN114945368A/zh active Pending
- 2020-11-30 WO PCT/FR2020/052228 patent/WO2021105641A1/fr unknown
- 2020-11-30 CA CA3163176A patent/CA3163176A1/fr active Pending
- 2020-11-30 US US17/780,148 patent/US20230013304A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021105641A1 (fr) | 2021-06-03 |
CN114945368A (zh) | 2022-08-26 |
CA3163176A1 (fr) | 2021-06-03 |
US20230013304A1 (en) | 2023-01-19 |
FR3103701B1 (fr) | 2021-11-26 |
FR3103701A1 (fr) | 2021-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2875010B1 (fr) | Derives de thiophenes utiles dans le traitement du diabete | |
EP2113502B1 (fr) | Composés de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires | |
EP0740654A1 (fr) | Inhibiteurs de la monoamine oxydase b, leurs procedes de preparation et leurs applications | |
CA2730302C (fr) | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson | |
TW202132289A (zh) | 作為肝臟x受體促效劑之1,2,4-㗁二唑衍生物 | |
EP2875026B1 (fr) | Derive d'imidazopyridine utiles dans le traitement du diabete | |
EP0533827B1 (fr) | Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP4065120A1 (fr) | Modulateurs de cftr de type n2-arylmethyl-4-haloalkyl-pyridazin-3-one pour le traitement de la mucoviscidose | |
WO2023276828A1 (fr) | Composition pharmaceutique pour la prévention et/ou le traitement d'une lésion rénale, et activateur d'autophagie | |
EP3518912B1 (fr) | Sel de metformine d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie | |
WO2006018544A1 (fr) | Compositions contenant un compose thiophenique ou benzothiophenique, presentant une activite inhibitrice de pompe nora | |
EP2931266B1 (fr) | Composition et kit comprenant des dérivés de pipérazine et de la metformine, leur utilisation dans le traitement du diabète | |
EP2953947A1 (fr) | 3,5-diaryl-azaindoles comme inhibiteurs de la protéine dyrk1a pour le traitement des déficiences cognitives liées au syndrome de down et à la maladie d'alzheimer | |
US20220110916A1 (en) | Antioxidant and Use Thereof | |
AU2018439206B2 (en) | Compounds useful as chaperone-mediated autophagy modulators | |
EP0294258A1 (fr) | Dérivés d'hydrazine, procédé d'obtention et compositions pharmaceutiques les contenant | |
EP2654752B1 (fr) | Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine | |
BE1003518A3 (fr) | Nouveaux derives de la methoxycarbonyl-2-n,n'-di-(trimethoxybenzoyle) piperazine, un procede pour leur preparation et compositions therapeutiques en contenant. | |
US20230330066A1 (en) | Vasodilator and Use Thereof | |
WO2012104538A1 (fr) | Nouveaux dérivés de 1, 5 - dihydropyrrol - 2 - one utiles pour le traitement paludisme ou d'autres maladies parasitaires et fongiques | |
WO2014162106A1 (fr) | Nouveaux derives de chalcone presentant une activite anti-allergique | |
JPH1045592A (ja) | 糖尿病合併症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220525 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITE CLAUDE BERNARD LYON 1 (UCBL) Owner name: ECOLE NORMALE SUPERIEURE DE LYON Owner name: INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) Owner name: UNIVERSITE DE ROUEN NORMANDIE Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Owner name: UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE |